Remove Blogging Remove Funding Remove Layoffs Remove San Diego
article thumbnail

Bio Roundup: Theranos Cuts, Alnylam Stops, Nobel Eats Its Own & More

Xconomy

military’s high-tech think tank DARPA described Safe Genes, a new program to fund safety measures that can be built into genome editing technology or counter its potential wayward effects. The funding could be as much as $100 million, and the first grants will be announced in 2017. Shares immediately fell more than 40 percent.

article thumbnail

Biotech Roundup: Moonshots, Pink Slips, Gilead, Brexit & More

Xconomy

—In other news from the moonshot day, Biden warned researchers in academia and industry that they would risk losing federal funding if they didn’t follow the law and report their clinical trial results to the public ClinicalTrials.gov database… IBM said it would deploy its Watson systems to help the U.S. .

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Biotech Roundup: Hellos, Goodbyes, “Cures” Delays And Trial News

Xconomy

Our San Diego editor Bruce Bigelow penned a personal goodbye to entrepreneur Larry Bock, who died last week of pancreatic cancer at the age of 56. million in funding, according to a regulatory filing. The week started on a reflective note. A UCSF cancer expert called XBiotech’s data release “bogus.”

News 40
article thumbnail

Bio Roundup: NY Rises, Prez Inks Cures, Ophthotech Crashes & More

Xconomy

Let’s get to the roundup… TOP STORIES —In what is likely the last major legislative action of his eight-year presidency, President Barack Obama signed into law the 21st Century Cures Act to boost NIH funding for projects his administration kickstarted. The bill also.

Funding 40
article thumbnail

Biotech Roundup: Kadmon Debt, Hemo Data, Loose Lips & More

Xconomy

Funding rounds: Cambridge-based Mersana Therapeutics closed a $33 million Series C round with the aim of testing its first drug, an antibody-drug conjugate for breast cancer called XMT-1522… Rockefeller University spinout Rgenix’s $33 million financing was the second largest for a privately held Manhattan biotech this year.

News 55
article thumbnail

Bio Roundup: Bosley’s Editas Exit, Bridge Bucks, CRISPR Crime & More

Xconomy

In a week of big personnel moves, none was more surprising than Editas Medicine CEO Katrine Bosley’s departure.

Guide 63
article thumbnail

Bio Roundup: Senate Drama, A.I. Stories, Data Dives, Shkreli & More

Xconomy

There is no Obamacare replacement, at least not as of this writing. The Senate Republicans are fractured, with a handful of conservatives and moderates each giving a cold shoulder to their chamber’s version of healthcare reform, the Better Care Reconciliation Act.

Writing 56